Biohaven Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BHVN | B9A.F | VIR | AAPG | 688177.SS | LKFT | |
|---|---|---|---|---|---|---|
| Market cap | 2.30B | 2.45B | 1.99B | 1.41B | 7.38B | 2.25B |
| P/E (TTM) | — | 250.7 | — | — | — | 3.2 |
| Forward P/E | -8.2 | — | -4.8 | -23.3 | -26.2 | -28.6 |
| Price/book | -23.4 | 1.2 | 2.1 | 16.9 | 171.3 | 12.2 |
| Dividend yield | — | 0.68% | — | — | — | — |
| 1-year change | +78.66% | +13.08% | +129.88% | −53.43% | −34.43% | +9.26% |
| Today | −2.37% | −0.29% | +4.90% | +11.75% | +2.95% | +6.03% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BHVN news ›Significant stock movers of October: Biohaven climbs, ArriVent dives
A renewed regulatory opening and a clinical setback sent two biotech stocks in opposite directions in October. Biohaven gained ground after the FDA agreed to review its rare disease resubmission, while ArriVent BioPharma plunged after its…
Biohaven Ltd. Stock 12‑Month Price Target Raised to $25, Implies 65% Upside
TradingView Biohaven Ltd. Stock 12‑Month Price Target Raised to $25, Implies 65% Upside - According to estimates from 13 analysts, Biohaven Ltd. stock's average price target has risen from $24.85 to $25, with forecasts rang
Biohaven (NYSE:BHVN) Stock Gets Price Target Boost from Canaccord Genuity Group
Posted by Kim Johansen on Nov 2nd, 2026 Biohaven (NYSE:BHVN – Get Free Report) had its price objective hoisted by stock analysts at Canaccord Genuity Group from $21.00 to $32.00 in a research report issued to clients and investors on…
Biohaven Q3 Loss Narrows as FDA Accepts Vyglxia NDA Resubmission
General and administrative expenses were $24.6 million, compared with $28.2 million a year earlier, a $3.6 million decrease the company attributed primarily to lower employee costs. Other expense, net was $2.9 million, compared with $3.8…
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
Oct 29, 2026 4:02pm EDT Third Quarter 2026 and Recent Business Highlights Kv7 Ion Channel Platform and Opakalim (BHV-7000) Vyglxia (troriluzole) in SCA: Selective Kv7 Ion Channel Activator (Opakalim): Lead TRAP and MoDE Extracellular…
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
NEW HAVEN, Conn. and OSAKA, Japan, Oct. 8, 2026 Tova Gardin, M.D., Chief Translational Officer of Biohaven, commented, "Pairing BHV-1300 with Ono's regional development and commercial excellence gives this portfolio its strongest and…
Ono extends I&I reach in $100M Biohaven deal for IgG degraders
Ono Pharmaceutical Co. Ltd. is paying $100 million up front to gain select Asian rights to Biohaven Ltd.’s small-molecule IgG degrader portfolio, including in Japan, South Korea and Taiwan, as it seeks to bolster its immunology and…
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy
One year after Biohaven's first TRAP degrader, BHV-1400, was highlighted in the Kidney Week opening plenary, Biohaven's second TRAP degrader for kidney disease expands its Yale-licensed platform into a growing nephrology franchise BHV-1420…
[Must-Read for Investors] The Reality and Risks of Drug Discovery Startups Learned from Biohaven [Why Do Biotech Stocks Move 50% on a Single News Item?]
→ You wake up one morning, open your stock chart, and find that a stock you hold has jumped by 50%. Or, without any warning, it has crashed by 50%. In the world of drug discovery biotech ventures with almost zero revenue, such extreme…
BiohavenPharmaHldg Meets 80-Plus Relative Strength Rating Benchmark
BiohavenPharmaHldg sees its Relative Strength Rating move into the 80-plus level. RESEARCH: IBD's 50 Most Sustainable Companies For 2026 One important metric to look for in a stock is an 80 or higher Relative Strength Rating.…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- tradingview.com4
- marketscreener.com3
- seekingalpha.com3
- businessupturn.com2
- investors.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 37 articles, not a forecast.